Intravenous valproate: effects on plasma and saliva phenytoin levels.
Plasma and saliva phenytoin was evaluated at fixed-time intervals after intravenous (IV) administration of 800 mg valproate in epileptics chronically treated with phenytoin monotherapy. A significant fall in plasma and a concurrent significant increase of the drug in saliva (which reflects the free amount in plasma) were observed, with maximal changes occurring at 30 to 90 minutes after valproate infusion. Present data indicate that valproic acid is able to displace phenytoin from plasma proteins, suggesting a critical evaluation of the routine phenytoin plasma proteins, suggesting a critical evaluation of the routine phenytoin plasma levels (which reflect free + bound fraction) when this drug is administered concurrently with sodium valproate.
D000293:Adolescent; D000328:Adult; D001798:Blood Proteins / Q000378:metabolism; D004347:Drug Interactions; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D010672:Phenytoin / Q000032:analysis* / Q000097:blood / Q000378:metabolism; D012463:Saliva / Q000032:analysis*; D014635:Valproic Acid / Q000008:administration & dosage / Q000494:pharmacology*
D001798:Blood Proteins; D014635:Valproic Acid; D010672:Phenytoin